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Previous studies have found an association between a single-nucleotide polymorphism 35 kb upstream of the
HLA-C locus (35 SNP), HLA-C expression, and HIV-1 set point viral loads. We show that the difference in
HLA-C expression across 35 SNP genotypes can be attributed primarily to the very low expression of a single
allelic product, HLA-Cw7, which is a common HLA type. We suggest that association of the 35 SNP and
HIV-1 load manifests as a result of linkage disequilibrium of this polymorphism with both favorable and
unfavorable HLA-C and -B alleles.
Infection with HIV-1 involves a complex interplay between
virus and host. After the acute phase of infection, an equilib-
rium is reached between HIV-1 and the immune system, re-
sulting in the decline of HIV-1 RNA levels to the widely
variable viral set point, a known (though imperfect) predictor
of time to progression to AIDS (36, 37). The early appearance
of HIV-1-specific CD8 T cells and their rapid selection of
escape mutants during the initial decline of viremia in primary
infection imply that this T-cell response plays a central role in
resolution of primary viremia and the long-term suppression of
viral replication (21, 34).
The major histocompatibility complex (MHC), located on
chromosome 6, contains the HLA class I and II genes, which
are the most polymorphic loci in humans (9). HLA class I
molecules play a significant role in the immune response
against HIV-1 by presenting viral peptides to CD8 T cells
(adaptive immunity) and by serving as ligands for killer cell
immunoglobulin-like receptors (KIRs) expressed on natural
killer (NK) cells (innate immunity). The central role of the
MHC region in HIV-1 control was highlighted by a recent
genomewide association study of variants that influence the
control of viral set point (17, 18). In Caucasian cohorts, two
single-nucleotide polymorphisms (SNPs) were identified that
associated with the HIV-1 set point, and a third was associated
with disease progression. All three SNPs were located in the
MHC region on chromosome 6. These findings have been
replicated with other independent Caucasian cohorts (10, 15,
31, 53, 55).
One minor allelic variant of an SNP (rs2395029) associated
with lower viral set points is located in the HLA complex P5
(HCP5) gene and is a tag for HLA-B*5701 (17), which is
associated with slow disease progression (2, 9, 25, 40, 42). The
second most significant polymorphism (rs9264942), accounting
for 6.5% of the variation in viral set point (18), is located 35 kb
upstream of the HLA-C gene (35 SNP), with the minor allele
(C) associating with a lower set point than the major allele (T).
The 35 SNP is also present in African-American populations
but does not correlate with viral set point (47, 49), which
suggests that the 35 SNP is a marker for another polymor-
phism and is not the causal SNP. Although HLA-B*5701 is in
linkage disequilibrium with the 35 SNP, both associate inde-
pendently with the viral load set point (17, 18).
The 35 C variant was associated with higher HLA-C
mRNA expression in Epstein-Barr virus (EBV)-transformed
B-cell lines, suggesting an inverse correlation between HLA-C
expression and viral load (51). However, the extreme polymor-
phism of HLA-C and posttranslational regulation of HLA class
I molecules may complicate this relationship (23, 33). The 35
SNP is known to be in strong linkage disequilibrium with
HLA-C alleles (Cw*0102, -0202, -0302, -0501, -0602, -0801,
-0802, -1202, -1203, and -1402 for the 35 C allele and
Cw*0303, -0304, -0401, -0701, -0702, -0704, -1502, -1504, -1505,
-1506, -1601, -1602, -1604, and -1701 for the 35 T allele) (17,
52), and each type may have its own intrinsic level of expres-
sion. Therefore, protein expression studies are needed to re-
solve the question of whether the 35 SNP is associated with
increased levels of surface HLA-C. Recently, it was reported
that surface expression of HLA-C varies significantly across
35 SNP genotypes and that the HLA-C alleles that are in
linkage disequilibrium with the 35 C allele are expressed at
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higher levels than those that are in linkage disequilibrium with
the 35 T allele (52). However, interpretation of this study is
complicated by the known cross-reaction with HLA-E of the
antibody used for the study (DT9) (7). Our results show that
when this cross-reaction is taken into account, the difference in
the levels of HLA-C expressed at the cell surface between 35
SNP genotypes is actually greater than previously realized.
However, we also show that nearly all of this difference can be
accounted for by the particularly low expression of HLA-Cw7,
which is in strong linkage disequilibrium with the 35 T allele.
Although HLA-Cw7 has been shown to associate with more
rapid progression of disease in HIV-1-infected patients (48), it
cannot account fully for association of the 35 SNP with lower
HIV-1 loads and slower progression to AIDS (17).
MATERIALS AND METHODS
Subjects. Peripheral blood mononuclear cells (PBMC) from healthy volun-
teers of European descent were isolated from whole blood by Ficoll-Hypaque
gradient centrifugation. Written informed consent was obtained from all volun-
teers under appropriate university regulations. Cryopreserved PBMC from 25
HIV-1-infected subjects of European descent were obtained from the CHAVI
001 and SCOPE (22) cohorts. All experiments on HIV-infected samples were
approved by the Oxford Tropical Research Ethics Committee.
35 SNP genotyping. Genomic DNAs from the healthy volunteers were geno-
typed for the 35 SNP by PCRs using a common forward primer (5-GGGTG
GTGCCAAGTATGAG-3) and alternative allele-specific reverse primers (5-A
GAAAGTCCCACAGTGCCTA-3 and 5-AGAAAGTCCCACAGTGCCTG-
3). Genotyping reaction mixtures also contained control primers that amplify a
constant region in the DRB1 locus (43). Thermocycling conditions were as
follows: 96°C for 1 min; 5 cycles of 96°C for 25 s, 70°C for 45 s, and 72°C for 45 s;
21 cycles of 96°C for 25 s, 65°C for 50 s, and 72°C for 45 s; and 4 cycles of 96°C
for 25 s, 55°C for 1 min, and 72°C for 2 min. Products were resolved in 2%
agarose gels and visualized under UV with ethidium bromide. This PCR assay
was validated by direct sequencing of a PCR product spanning the 35 SNP for
the first 100 samples typed.
Monoclonal antibodies and flow cytometry. MEM-E/06 and MEM-E/08 were
obtained from Santa Cruz; anti-human HLA-E (3D12), anti-human HLA-A,B,C
(W6/32), and a mouse IgG2b kappa isotype control (clone MPC-11) were ob-
tained from BioLegend; CD3-PerCP (clone SK7) was obtained from Becton
Dickinson; a mouse IgG2b-fluorescein isothiocyanate (FITC) (clone MOPC-
141) isotype control and mouse anti-human MHC class I (W6/32)–FITC were
obtained from Sigma; and rat anti-mouse kappa (clone 187.1)–FITC was ob-
tained from Southern Biotech. Monoclonal antibody DT9 was affinity purified on
protein A-Sepharose beads (Sigma-Aldrich) from a hybridoma supernatant by
standard procedures and conjugated using a FluoroTag FITC conjugation kit
(Sigma).
For all cell surface staining, 1 million thawed PBMC were washed once with
phosphate-buffered saline (PBS; Sigma-Aldrich) and then stained with Live/
Dead stain (Invitrogen) per the manufacturer’s instructions. For direct antibody
staining, cells were then incubated on ice for 15 min with appropriate antibodies.
For indirect antibody staining, cells were incubated with primary antibodies (15
min on ice), free secondary antibody binding sites were blocked with mouse
serum (Southern Biotech), and then cells were incubated with secondary anti-
body and anti-CD3–PerCP (15 min on ice). Cells were washed twice between
each step with flow cytometry buffer (PBS containing 0.5% bovine serum albu-
min [BSA]). After being stained, cells were washed again, fixed with Cell Fix
buffer (Becton Dickinson), and analyzed using a CyAn flow cytometer and
FlowJo software (Treestar, Inc.).
Characterization of monoclonal antibodies. LABScreen single-antigen class I
Combi beads (One Lambda), each coated with a single HLA allotype (46), were
incubated with DT9, 3D12, MEM-E/06, MEM-E/08, and W6/32 antibodies for 30
min at room temperature, washed 3 times with PBS, incubated at room temper-
ature for 30 min with goat anti-mouse IgG–R-phycoerythrin (R-PE) (Invitro-
gen), washed 3 times as described before, and analyzed on a LABScan 100 flow
analyzer.
The specificity of the monoclonal antibody panel for HLA-E was tested by
binding to HLA-E on transfected 721.221 AEH cells (29), a gift from V. Braud
(University of Nice).
RESULTS
Determining the specificity and applicability of HLA-C and
HLA-E antibodies. The study of individual surface HLA mol-
ecules is complicated by the scarcity of allele-specific antibod-
ies. The monoclonal antibody DT9 (7), originally raised against
MHC class I proteins from cottontop tamarins, is the only
available HLA-C-specific antibody that does not extensively
cross-react with HLA-A or -B alleles. However, immunopre-
cipitation and one-dimensional isoelectric focusing (1D-IEF)
studies confirmed that it also recognizes the nonclassical
HLA-E protein (6, 7). A recent study showing a correlation
between surface HLA-C expression and the 35 SNP dis-
counted cross-reaction of DT9 with HLA-E, as it was shown
that the HLA-E-specific antibody MEM-E/08 stains a cell line
transfected with HLA-E but does not stain PBMC (52). How-
ever, it has previously been reported that MEM-E/08 cannot
be used to detect HLA-E on PBMC by flow cytometry (32).
Therefore, we decided to reexamine cell surface expression of
HLA-E by PBMC to better understand DT9 staining.
In addition to MEM-E/08, we tested two other commercially
available antibodies that are nominally specific for HLA-E
(MEM-E/06 and 3D12) (29, 38, 44), using 220.221 cells trans-
fected with HLA-E. As can be seen in Fig. 1A, the levels of
staining with all of these antibodies were similar to that with
DT9, confirming that they all recognize HLA-E, at least as
expressed by transfected cells. When we used these antibodies
to stain PBMC from healthy volunteers, however, we saw
marked differences in the levels of staining. Consistent with
previous reports (32, 52), we did not see staining of PBMC with
MEM-E/08 (Fig. 1B). In contrast, the level of staining seen
with MEM-E/06 varied considerably from donor to donor,
suggesting that this antibody may cross-react with other HLA
proteins. Finally, we observed fairly constant levels of staining
of PBMC with 3D12.
The possibility that MEM-E/06 cross-reacts with other class
I proteins prompted us to test the specificity of all of the
antibodies used. To do this, we employed the LABScreen sys-
tem, a Luminex assay that allows detection of antibody cross-
reactions with 97 common HLA class I alleles spanning HLAs
A, B, and C. In addition to testing the three HLA-E antibodies,
we also tested DT9. Since there can be considerable bead-to-
bead differences in the amount of HLA protein present on the
individual antigen beads (S. Fuggle and S. Page, personal com-
munication), we used binding of the pan-class I antibody
W6/32 (3) to normalize the results. While DT9 was highly
specific for HLA-C and cross-reacted only with the rare HLA-
A*8001 and -B*7301 alleles (Fig. 2A), confirming previous
findings (52), MEM-E/06 did indeed show extensive cross-
reactions with many HLA-A, -B, and -C proteins (Fig. 2B), as
previously reported (32, 38), and there was good correlation
with the levels of PBMC staining described above (data not
shown). Cross-reaction of MEM-E/06 with HLA-A*0301 but
not with HLA-A*0201 was confirmed by immunoprecipitation
and 1D-IEF, using 220.221 cells transfected with these HLAs
(data not shown). Much less cross-reaction was seen for both
MEM-E/08 and 3D12 (Fig. 2C and D), and for 3D12, the level
of binding seen with the beads did not translate into cross-
reaction with these HLAs at the cell surface.
Although at present we cannot rule out cross-reaction with
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other nonclassical HLA proteins, it appears that 3D12 is in-
deed specific for HLA-E and that HLA-E is present on the
surfaces of cells at levels detectable by flow cytometry. It is not
clear why MEM-E/08 stains HLA-E-transfected cells and not
PBMC, but one possible explanation is that this antibody is
actually specific for a misfolded HLA heavy chain which may
be present at increased levels on the surfaces of transfected
cells.
DT9 staining of PBMC from healthy and HIV-1-infected
subjects. In the absence of a truly HLA-C-specific antibody,
DT9 (which recognizes both HLA-C and HLA-E) was used to
stain cryopreserved PBMC from 28 HIV-1-uninfected subjects
selected on the basis of homozygosity of their 35 SNP geno-
type (both TT and CC) and the absence of the HLA alleles
(A*8001 and B*7301) that cross-react with DT9. There was a
significantly higher level of DT9 staining of lymphocytes (CD3-
FIG. 1. Staining of 220.221AEH cells and PBMC with DT9 and HLA-E-specific antibodies. (A) Staining of the 220.221AEH cell line, showing
unstained cells (filled black area) and cells stained with MEM-E/06 (filled brown area), MEM-E/08 (red line), 3D12 (green line), and DT9 (blue
line). (B) Representative staining of CD3 lymphocytes (gating on appropriate forward and side scatter, live cells, and CD3 expression) from a
healthy volunteer (HLA-A2, -B35, -B44, -Cw4, and -Cw5), showing unstained cells (filled black area) and cells stained with MEM-E/06 (filled
brown area), MEM-E/08 (red line), 3D12 (green line), DT9 (blue line), and an IgG2b isotype control (filled gray area).
FIG. 2. Characterization of monoclonal antibodies DT9, 3D12, MEM-E/06, and MEM-E/08 against 97 common HLA class I allotypes. Binding
was determined for DT9 (A), MEM-E/06 (B), MEM-E/08 (C), and 3D12 (D), using beads coated with recombinant HLA-A (blue), -B (green),
and -C (red) proteins, and normalized relative to the binding of W6/32 (the horizontal line corresponds to the level of binding seen with W6/32).
Values shown represent the averages for three runs; the maximum standard errors of the means were 0.06 (DT9), 0.05 (MEM-E/06), 0.012
(MEM-E/08), and 0.01 (3D12). The order of the HLA allotypes tested (along the x axis) was as follows: A0101, -0201, -0203, -0206, -0301, -1101,
-1102, -2301, -2402, -2403, -2501, -2601, -2901, -2902, -3001, -3002, -3101, -3201, -3301, -3303, -3401, -3402, -3601, -4301, -6601, -6602, -6801, -6802,
-6901, and -7401, B8001, -0702, -0801, -1301, -1302, -1401, -1402, -1501, -1502, -1503, -1510, -1511, -1512, -1513, -1516, -1801, -2705, -2708, -3501,
-3701, -3801, -3901, -4001, -4002, -4006, -4101, -4201, -4402, -4403, -4501, -4601, -4701, -4801, -4901, -5001, -5101, -5102, -5201, -5301, -5401, -5501,
-5601, -5701, -5703, -5801, -5901, -6701, -7301, -7801, -8101, and -8201, and Cw0102, -0202, -0302, -0303, -0304, -0401, -0501, -0602, -0702, -0801,
-1203, -1402, -1502, -1601, -1701, and -1802.
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positive cells) from CC subjects than of those from TT subjects
(P  0.0459; Mann-Whitney test) (Fig. 3A). When the TT
subjects were subdivided based on their HLA-C alleles, DT9
staining of TT subjects who were homozygous for HLA-Cw*07
was significantly lower than that for both CC subjects, who
were all HLA-Cw*07 negative (P  0.004), and TT subjects
who were either heterozygous for or did not have HLA-Cw*07
(P  0.0007) (Fig. 3B). There was no significant difference in
the DT9 staining of PBMC from TT subjects who were not
homozygous for HLA-Cw*07 and CC subjects. These findings
imply that low HLA-Cw7 levels could account for the differ-
ences in HLA-C expression previously described as high levels
associated with the 35 CC genotype.
Lymphocytes from 25 HIV-1-infected subjects were also
stained with DT9. As seen before, DT9 staining of CC subjects
was just significantly higher than staining of TT subjects (P 
0.0413) (Fig. 3C), and again, this difference in staining was
even more striking with TT subjects who were also homozygous
for HLA-Cw*07 (Fig. 3D) (P  0.0043). Furthermore, there
was no significant difference in median fluorescence intensity
values comparing HIV-1-uninfected and -infected subjects,
suggesting that, at least in chronically infected subjects, HIV-1
does not upregulate expression of the HLA-C protein.
Quantifying HLA-C on the cell surface. In order to deter-
mine the contribution of HLA-C to DT9 binding, saturating
amounts of DT9 and 3D12 were used to stain lymphocytes
from HIV-1-uninfected subjects in indirect antibody binding
assays (Fig. 4 and 5). As with direct DT9 staining, the low levels
of staining observed in these indirect binding assays are con-
sistent with cell surface levels of HLA-C protein being 10-fold
less than those of HLA-A and -B proteins (50). Despite the
consistently low staining with 3D12, there was a significant
difference in median fluorescence intensity between unstained
cells and cells stained with 3D12 (P  0.0001; Mann-Whitney
test), confirming surface expression of HLA-E (Fig. 5A), and
when subjects were grouped by 35 SNP genotype, there was
no significant difference in 3D12 binding (Fig. 5B). As seen
before, differences in DT9 staining in this indirect staining
assay were driven by the low levels of binding for TT individ-
uals who were homozygous for HLA-Cw*07 (Fig. 5C).
There was no statistically significant correlation between
3D12 and DT9 binding (Spearman test; r  0.3495; P 
0.0583) (Fig. 5D). These data imply that the differences seen
in DT9 staining are the result of differences in HLA-C
binding alone. Furthermore, the constant contribution of
surface HLA-E to DT9 binding means that the difference in
FIG. 3. Direct DT9 staining of live CD3 T lymphocytes from 35 SNP homozygotes. PBMC from HIV-1-uninfected (A and B) and
chronically HIV-1-infected (C and D) subjects were stained with DT9. DT9 median fluorescence intensities (MFI; y axis) were corrected for
background autofluorescence of unstained cells. 35 SNP genotypes are indicated on the x axis. In panels B and D, “other” refers to 35 TT
individuals who were not homozygous for HLA-Cw7. P values were calculated using the Mann-Whitney test.
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HLA-C surface expression between the CC and TT subjects
is greater than previously recognized. To better quantify this
difference, we calculated the ratio of HLA-C (3D12 staining
subtracted from DT9 staining) to total class I protein on the
cell surface (measured by W6/32 staining). The proportions
of actual HLA-C binding to W6/32 binding ranged from 1.0
to 4.6%, 1.0 to 3.4%, and 0.4 to 2.6% for 35 CC, CT, and
TT subjects, respectively. There was a significant difference
in the ratios of HLA-C to W6/32 binding between 35 CC
and TT subjects (Fig. 5E) (P  0.0061; Mann-Whitney test),
but again, this difference was driven exclusively by the low
expression of HLA-Cw7 (P  0.0032 for comparing 35 CC
with 35 TT subjects homozygous for HLA-Cw*07). As
before, there was no significant difference in the ratios of
HLA-C to W6/32 binding between 35 CC and TT subjects
who were not homozygous for HLA-Cw*07 (P  0.0896).
From this observation, we concluded that 35 CC subjects
expressed 1.76 times more HLA-C molecules than 35 TT
subjects considered as a whole but 5 times more HLA-C
molecules than 35 TT subjects who were homozygous for
HLA-Cw*07. Therefore, the protective 35 SNP genotype
does not associate with increased expression of HLA-C.
FIG. 4. Indirect staining of lymphocytes with 3D12, DT9, and W6/32 antibodies. Representative staining results are shown for CD3
lymphocytes (gated on appropriate forward and side scatter, live cells, and CD3 expression) from two HIV-1-uninfected subjects: a 35 TT subject
(homozygous for HLA-Cw*07) (A) and a 35 CC subject (HLA-Cw*05/06) (B). Data are shown for unstained cells (filled black area), 3D12
staining (green), DT9 staining (blue), and W6/32 (pan-class I) staining (gray).
FIG. 5. Indirect staining of lymphocytes from 30 healthy volunteers, using 3D12 and DT9. (A) Paired comparisons of MFI of unstained cells
and cells stained with 3D12. (B and C) Indirect staining (with 3D12 and DT9, respectively) of live CD3 lymphocytes, corrected for background
autofluorescence of unstained cells. (D) Correlation of background-corrected DT9 and 3D12 staining. (E) Ratios of HLA-C levels (3D12 staining
subtracted from DT9 staining) to total class I protein levels (W6/32 staining). For panels B to E, red and half-red symbols denote individuals
homozygous and heterozygous for HLA-Cw*07, respectively. Statistical significance was calculated using the Mann-Whitney test.
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Rather, the nonprotective allele associates with the greatly
reduced expression of a single HLA-C allele, the Cw*07
allele.
DISCUSSION
Previous studies of Caucasians have indicated that a single-
nucleotide polymorphism 35 kb upstream of the HLA-C gene
associates with control of the HIV-1 set point (17, 18) as well
as with a slower progression to a CD4 count below 200 and an
increased time to death (52). Transcriptional data showing that
this SNP associates with differences in HLA-C expression lev-
els and the linkage of 35 SNP alleles with HLA-C alleles (17,
52) have all been taken as evidence that this SNP is a marker
for the HLA-C locus. As a result, there has been much spec-
ulation on a role for HLA-C in controlling HIV-1 infection.
HIV-1 selectively downregulates surface HLA-A and -B, but
not HLA-C and -E, via the action of the Nef protein (11–13,
56). The infected cells may therefore be relatively resistant to
HLA-A- and -B-restricted CD8 T-cell lysis but continue to
express HLA-C. While it has been shown that recognition of
infected cells by HLA-C-restricted CD8 T cells is unaffected by
HIV-1 Nef expression (1), these responses are relatively weak
(4, 25) and are consistently associated with high levels of
viremia in HIV-1-infected subjects, even when targeting the
Gag protein (26). This suggests that they contribute little to
viral control in vivo. HLA-C molecules also act as ligands for
the inhibitory KIR2DL receptors (28, 45), so infected cells
expressing high levels of HLA-C may be less vulnerable to NK
cell recognition (1, 12, 13). However, it is not known whether
the level of HLA-C expressed by the target cell is critical, and
in addition, NK cells lacking inhibitory receptors for HLA-C
and HLA-E molecules would still be able to kill HIV-1-in-
fected T cells (5).
The prevailing model for the effects of the protective 35 C
allele is that it is associated with higher cell surface levels of
HLA-C protein than those with the nonprotective T allele (17,
18, 30, 48, 52). Although DT9, the best available anti-HLA-C
antibody, was used to provide support for this hypothesis, this
antibody is known to cross-react with HLA-E (7). It was sug-
gested that DT9 binding to lymphocytes may be entirely spe-
cific for HLA-C, based on the observation that the nominally
HLA-E-specific antibody MEM-E/08 does not stain lympho-
cytes (52). However, we found that the HLA-E-specific anti-
body 3D12, which does not cross-react significantly with any
HLA-A, -B, or -C allotype, binds to lymphocytes. Thus,
HLA-E is expressed at low levels on the surfaces of lympho-
cytes, consistent with earlier data showing that lymphocytes
express HLA-E (5, 14, 41). We found that there was no sig-
nificant difference in 3D12 staining when subjects were
grouped according to their 35 SNP genotype. Therefore, our
results show not only that the differences in DT9 staining
associated with these genotypes are due to differences in
HLA-C surface expression but also that the difference between
HLA-C expression levels in donors with 35 CC and TT alleles
is greater than previously recognized. However, our results for
DT9 staining also show an important difference from those
reported previously (52). Like Thomas et al. (52), we observed
consistently higher levels of DT9 staining of cells from 35 CC
subjects than of those from 35 TT subjects, both for healthy
volunteers (P  0.0459) and for individuals infected with
HIV-1 (P  0.0413); we also found considerable overlap in the
ranges of DT9 staining levels between CC and TT subjects,
reflecting a wide spread of HLA-C expression across the dif-
ferent alleles. However, in our data set, cells from TT subjects
homozygous for HLA-Cw*07 had the least DT9 staining, by far
(Fig. 3). Indeed, the difference in staining levels between CC
subjects and TT subjects homozygous for HLA-Cw*07 was
highly significant (P  0.004 for healthy volunteers and P 
0.0043 for HIV-1-infected individuals). The difference in stain-
ing between TT subjects homozygous for HLA-Cw*07 and all
other TT subjects was highly significant for healthy volunteers
(P  0.0007) but less significant for HIV-1-infected individuals
(P  0.0196). Importantly, there was no statistically significant
difference in staining between CC subjects and TT subjects if
HLA-Cw*07 homozygotes were excluded, both for the healthy
volunteers and for the HIV-1-infected subjects. Note that a
similar pattern of particularly low DT9 antibody binding to
HLA-Cw7 was seen in the data on the staining of HIV-1-
uninfected subjects presented by Thomas et al. (52).
Even when the contribution of the constant background of
surface HLA-E expression to the level of DT9 staining for the
healthy volunteer samples is taken into account, the picture
does not change. Although the significance of the difference in
expression levels increased between CC and TT subjects (P 
0.0061) (Fig. 5E), this difference was still driven entirely by the
very low staining of cells from the HLA-Cw*07 homozygotes
(P  0.0032 for CC versus TT Cw*07/Cw*07 subjects and P 
0.0896 for CC versus TT non-Cw*07/Cw*07 subjects). Overall,
we estimate that levels of surface HLA-C expression were
approximately 1.76-fold greater for PBMC from CC subjects
than for cells from TT subjects, but this difference was almost
all accounted for by the approximately 5-fold-decreased ex-
pression of HLA-C in 35 TT donors who were also homozy-
gous for HLA-Cw*07 compared with that in 35 CC subjects.
Therefore, we concluded that the 35 SNP is actually most
strongly associated with intrinsically low expression of HLA-
Cw7 rather than with high expression of several 35 C-asso-
ciated HLA-C allotypes. We cannot exclude, however, the pos-
sibility that other HLA-C alleles may also have different
intrinsic levels of expression that could contribute to the over-
all levels of surface staining.
Despite the evidence that HLA-C-restricted CD8 T cells
contribute little to the control of HIV-1 at the population level,
it is still possible that significantly reduced expression of HLA-
Cw7 could have significant effects on an individual level. Low
expression of HLA-Cw7 could result in less effective presen-
tation of peptides to CD8 T cells and in less control of viral
replication. Low expression could also mean positive selection
of fewer HLA-Cw7-restricted T cells in the thymus. In addi-
tion, by analogy with the suggestion that much of the benefit of
protective HLA-B alleles arises from the presentation of par-
ticularly effective peptides (27), it is possible that HLA-Cw7
might bind to less-favorable peptides in HIV-1. Consistent with
these possibilities, Fellay et al. showed that of all the HLA-C
alleles, HLA-Cw*07 is significantly associated with the highest
mean viral load set point (17). However, the exclusion of sub-
jects homozygous for HLA-Cw*07 does not abolish the asso-
ciation of the 35 SNP with control of HIV-1 infection. This
suggests that lower expression of HLA-Cw7 (a particularly
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common allele in people of European descent [26.0 to 66.2%]
[39]) contributes only a part of the protective effect marked by
the 35 SNP. The International HIV Controllers Study re-
cently implicated seven HLA class I alleles with control of
HIV-1 and showed that HLA-Cw*07 is a risk allele associated
with high viremia and more rapid disease progression (48).
Indeed, it is becoming increasingly clear that genomewide
association studies of human diseases can be hampered by the
complexity of linkage disequilibrium patterns in the MHC re-
gion. These studies capture the majority of common variants in
the genome that explain only a small proportion of heritability,
while low-frequency polymorphisms, each conferring an inter-
mediate increase in risk, can explain a significant proportion of
the genetic susceptibility to common diseases (19, 20). Re-
cently, Dickson et al. argued that rare variants can create
synthetic association signals in genomewide association studies
by occurring more often in association with one of the alleles
of an SNP, which would therefore synthetically confer an in-
creased risk for disease (16). We suggest, therefore, that the
35 SNP effect is an example of just such a synthetic associ-
ation, arising as a compound effect of linkage disequilibrium.
Specifically, HLA-C alleles associated with rapid progression
tend to be in linkage disequilibrium with the 35 T allele,
while protective alleles such as HLA-B*57 and -B*27 are in
linkage disequilibrium with the protective 35 C allele. Stud-
ies on immune responses in HIV-1 have shown that HLA-B
allotypes most frequently induce detectable T-cell responses
and that these are generally of greater magnitude than re-
sponses restricted by either HLA-A or HLA-C. Therefore,
HLA-B-restricted CD8 T-cell responses play a greater role in
the immune response against HIV-1 infection (4, 25, 26). It is
very well established that pairs of HLA-B and HLA-C alleles
are in linkage disequilibrium and that particular haplotypes
can be either protective (B*14-Cw*0802 in Caucasians and
B*3910-Cw*1203 and B*8101-Cw*0401 in Africans) or harm-
ful (B*35-Cw*0401 in Caucasians) in the context of HIV-1
disease progression (8, 17, 30, 48). HLA-Cw*07 is in strong
linkage disequilibrium with HLA-B*07 and -B*08, and the
latter is known to have an unfavorable impact on HIV-1 dis-
ease progression (9, 24, 35, 42, 48, 54). Although particular
HLA alleles, particularly those of the HLA-B locus, can have a
strong individual impact, overall HIV-1 control is likely to be
influenced by the combination of all HLA alleles present (30).
In conclusion, it is extremely unlikely that the association of
the 35 SNP with control of HIV-1 infection is a direct result
of the SNP itself, and the role of increased expression of
HLA-C allotypes associated with the 35 C allele (18, 52) is
uncertain. Our data imply that it is the particularly low expres-
sion of the 35 T-associated HLA-Cw*07 allele that contrib-
utes substantially to the low HLA-C expression associated with
the 35 T allele, and possibly to the relatively high risk of
disease progression.
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